Ignite Creation Date:
2024-05-06 @ 8:41 AM
Last Modification Date:
2024-10-26 @ 12:03 PM
Study NCT ID:
NCT02797977
Status:
COMPLETED
Last Update Posted:
2023-06-22
First Post:
2016-05-23
Brief Title:
A Phase 12 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects
Sponsor:
Sierra Oncology LLC - a GSK company
Organization:
Sierra Oncology LLC - a GSK company
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Advanced Solid Tumors |
Keywords:
| Name | View |
|---|---|
| Genetic biomarkers | View |
| Replication Stress | View |
| Advanced solid tumors | View |
| CCNE1 | View |
| TP53 | View |
| BRCA1 | View |
| BRCA2 | View |
| MYC | View |
| RAD50 | View |
| Fanconi anemia | View |
| Cell Cycle | View |
| High grade serious ovarian cancer | View |
| Small cell lung cancer | View |
| Soft tissue sarcoma | View |
| Cervicalanogenital cancer | View |
| Phase 1 | View |
| Phase 2 | View |
| Dose escalation | View |
| Chk1 inhibitor | View |
| Checkpoint Kinase 1 | View |
| Synthetic lethality | View |
| Next-Generation Sequencing | View |